{"classes":[{"categories":[{"measurements":[{"comment":"Upper CI not calculable due to insufficient number of events.","groupId":"OG000","lowerLimit":"2.3","upperLimit":"NA","value":"14.6"},{"comment":"Median and upper CI not calculable due to insufficient number of events.","groupId":"OG001","lowerLimit":"1.9","upperLimit":"NA","value":"NA"},{"comment":"Upper and lower CI not calculable due to insufficient number of events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"4.7"},{"comment":"Median and CI not calculable due to insufficient number of events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"DoR was measured from the date the participant first met the criteria of an OR to the date that the participant progressed or until death from any cause during the period of disease assessments. Participants without progression or death were censored at the date of the last disease assessment. Participants who received subsequent anticancer therapy were censored at the date of last disease assessment before subsequent anticancer therapy. The median duration of response and corresponding 95% CI was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG000","title":"KRAS/NRAS WT"},{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG001","title":"KRAS/NRAS Mut"},{"description":"Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.","id":"OG002","title":"KRAS/NRAS Missing"},{"description":"Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.","id":"OG003","title":"CXCR4/2 High"},{"description":"Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.","id":"OG004","title":"CXCR4/2 Low"}],"paramType":"MEDIAN","populationDescription":"PP Analysis Set: Included participants who received at least 1 dose of tipifarnib and had a baseline disease assessment and at least 1 postbaseline disease assessment. Only participants who met the criteria for an OR and progressed or died were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Up to approximately 15 months","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}